SCHEMBL23258237

SCHEMBL23258237

Cc1cc(NCCO)nc(NC(=O)Nc2ccc(C(F)(F)F)cc2)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.49
MAPK14 Q16539 2/20 0.46
BRAF P15056 1/20 0.46
KDR P35968 1/20 0.46
TNNI3K Q59H18 1/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
ALDH1A1 P00352 1/20 0.45
TSHR P16473 1/20 0.45
MAPT P10636 2/20 0.44
HTT P42858 1/20 0.44
RAB9A P51151 1/20 0.44
DOT1L Q8TEK3 1/20 0.44
MTOR P42345 2/20 0.43
BAZ1A Q9NRL2 1/20 0.43
APOBEC3A P31941 1/20 0.42
APOBEC3G Q9HC16 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
PSEN1 P49768 1/20 0.42
PSEN2 P49810 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23258996 0.93 DOT1L (0.48) EPHX2MAPK14BRAFKDRTNNI3K
SCHEMBL23258982 0.91 MEN1 (0.55) EPHX2MAPK14BRAFKDRTNNI3K
SCHEMBL23258997 0.90 SMN1; SMN2 (0.49) EPHX2MAPK14MEN1KMT2AALDH1A1
SCHEMBL23258951 0.90 EPHX2 (0.43) EPHX2MAPK14BRAFKDRTNNI3K
SCHEMBL23258616 0.89 DOT1L (0.49) EPHX2MAPK14MEN1KMT2AALDH1A1
SCHEMBL18038077 0.89 DNM2 (0.45) EPHX2MEN1KMT2AALDH1A1TSHR
SCHEMBL23258618 0.88 DOT1L (0.50) EPHX2MAPK14MEN1KMT2AALDH1A1
SCHEMBL23259089 0.88 DNM2 (0.47) EPHX2BRAFMEN1KMT2AALDH1A1
SCHEMBL23259073 0.88 BRAF (0.55) MAPK14BRAFKDRTNNI3KMEN1
SCHEMBL23258221 0.87 SMN1; SMN2 (0.49) MEN1KMT2AALDH1A1MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230271926-A1 INHIBITION OF OLIG2 ACTIVITY Curtana Pharmaceuticals, Inc. 2023-08-31 US disclosed
US-20230271926-A1 INHIBITION OF OLIG2 ACTIVITY Curtana Pharmaceuticals, Inc. 2023-08-31 US disclosed
US-11691951-B2 Inhibition of Olig2 activity Curtana Pharmaceuticals, Inc. (US) 2023-07-04 US disclosed
US-11691951-B2 Inhibition of Olig2 activity Curtana Pharmaceuticals, Inc. (US) 2023-07-04 US disclosed
US-20210347739-A1 INHIBITION OF OLIG2 ACTIVITY Curtana Pharmaceuticals, Inc. 2021-11-11 US disclosed
US-20210114991-A1 INHIBITION OF OLIG2 ACTIVITY Curtana Pharmaceuticals, Inc. 2021-04-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210114991-A1 INHIBITION OF OLIG2 ACTIVITY GLI2, ING2, GMFG EPHX2 294/4885MAPK14 2108/4885BRAF 1334/4885
US-11691951-B2 Inhibition of Olig2 activity GLI2, ING2, GMFG EPHX2 294/4885MAPK14 2108/4885BRAF 1334/4885
US-20210347739-A1 INHIBITION OF OLIG2 ACTIVITY GLI2, ING2, GMFG EPHX2 294/4885MAPK14 2108/4885BRAF 1334/4885
US-20230271926-A1 INHIBITION OF OLIG2 ACTIVITY GLI2, ING2, GMFG EPHX2 294/4885MAPK14 2108/4885BRAF 1334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.